title: Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage.
abstract: BACKGROUND
  Immune recognition of foreign proteins by T cells hinges on the formation of a ternary complex sandwiching a constituent peptide of the protein between a major histocompatibility complex (MHC) molecule and a T cell receptor (TCR). Viruses have evolved means of "camouflaging" themselves, avoiding immune recognition by reducing the MHC and/or TCR binding of their constituent peptides. Computer-driven T cell epitope mapping tools have been used to evaluate the degree to which particular viruses have used this means of avoiding immune response, but most such analyses focus on MHC-facing 'agretopes'. Here we set out a new means of evaluating the TCR faces of viral peptides in addition to their agretopes, integrating evaluations of both sides of the ternary complex in a single analysis.
  
  
  METHODS
  This paper develops what we call the Janus Immunogenicity Score (JIS), bringing together a well-established method for predicting MHC binding, with a novel assessment of the potential for TCR binding based on similarity with self. Intuitively, both good MHC binding and poor self-similarity are required for high immunogenicity (i.e., a robust T effector response).
  
  
  RESULTS
  Focusing on the class II antigen-processing pathway, we show that the JIS of T effector epitopes and null or regulatory epitopes deposited in a large database of epitopes (Immune Epitope Database) are significantly different. We then show that different types of viruses display significantly different patterns of scores over their constituent peptides, with viruses causing chronic infection (Epstein-Barr and cytomegalovirus) strongly shifted to lower scores relative to those causing acute infection (Ebola and Marburg). Similarly we find distinct patterns among influenza proteins in H1N1 (a strain against which human populations rapidly developed immunity) and H5N1 and H7N9 (highly pathogenic avian flu strains, with significantly greater case mortality rates).
  
  
  CONCLUSIONS
  The Janus Immunogenicity Score, which integrates MHC binding and TCR cross-reactivity, provides a new tool for studying immunogenicity of pathogens and may improve the selection and optimization of antigenic elements for vaccine design.
authors.forename: Lu
authors.initials: L
authors.lastname: He
authors.forename: Anne S
authors.initials: AS
authors.lastname: De Groot
authors.forename: Andres H
authors.initials: AH
authors.lastname: Gutierrez
authors.forename: William D
authors.initials: WD
authors.lastname: Martin
authors.forename: Lenny
authors.initials: L
authors.lastname: Moise
authors.forename: Chris
authors.initials: C
authors.lastname: Bailey-Kellogg
mesh_terms: D000818:Animals; D019295:Computational Biology / Q000379:methods*; D003429:Cross Reactions; D016208:Databases, Factual; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology; D008285:Major Histocompatibility Complex; D008954:Models, Biological; D008958:Models, Molecular; D009976:Orthomyxoviridae Infections / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D014764:Viral Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000737:chemistry / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology; D014780:Viruses / Q000276:immunology*
chemical_list: D018984:Epitopes, T-Lymphocyte; D000949:Histocompatibility Antigens Class II; D011948:Receptors, Antigen, T-Cell; D014764:Viral Proteins; D014765:Viral Vaccines
references.citation: Vaccine. 2011 Apr 12;29(17):3299-309
references.pmid: 21349362
references.citation: Nature. 1988 Aug 4;334(6181):395-402
references.pmid: 3043226
references.citation: Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):95-105
references.pmid: 15687033
references.citation: J Virol. 2011 Feb;85(3):1310-21
references.pmid: 21084470
references.citation: J Biomed Biotechnol. 2010;2010:
references.pmid: 20706613
references.citation: Cell Immunol. 2006 Dec;244(2):148-53
references.pmid: 17445787
references.citation: J Clin Endocrinol Metab. 2006 Jun;91(6):2286-94
references.pmid: 16595602
references.citation: Biochim Biophys Acta. 2011 Feb;1808(2):522-9
references.pmid: 20451491
references.citation: Vaccine. 1995 Apr;13(6):581-91
references.pmid: 7483779
references.citation: PLoS Comput Biol. 2012;8(3):e1002412
references.pmid: 22396638
references.citation: Immunol Cell Biol. 2002 Jun;80(3):255-69
references.pmid: 12067413
references.citation: Curr Opin Immunol. 2008 Oct;20(5):575-80
references.pmid: 18678247
references.citation: Hum Vaccin Immunother. 2013 Jul;9(7):1577-86
references.pmid: 23584251
references.citation: AIDS Res Hum Retroviruses. 2001 May 20;17(8):703-17
references.pmid: 11429111
references.citation: Crit Rev Immunol. 2012;32(2):139-55
references.pmid: 23216612
references.citation: J Clin Invest. 2001 Dec;108(11):1677-85
references.pmid: 11733563
references.citation: Bioinformatics. 2009 Jun 15;25(12):i39-44
references.pmid: 19478014
references.citation: Immunol Today. 1998 Sep;19(9):395-404
references.pmid: 9745202
references.citation: AIDS Res Hum Retroviruses. 1997 May 1;13(7):529-31
references.pmid: 9135870
references.citation: Trends Immunol. 2010 Feb;31(2):71-9
references.pmid: 20004147
references.citation: Front Immunol. 2012 Nov 29;3:364
references.pmid: 23230441
references.citation: PLoS Comput Biol. 2011 Oct;7(10):e1002220
references.pmid: 22022257
references.citation: Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14560-6
references.pmid: 15297608
references.citation: Nat Rev Immunol. 2003 Mar;3(3):253-7
references.pmid: 12658273
references.citation: PLoS One. 2012;7(12):e51957
references.pmid: 23251663
references.citation: Hum Vaccin. 2006 May-Jun;2(3):119-28
references.pmid: 17012903
references.citation: J Immunol. 1998 Apr 1;160(7):3363-73
references.pmid: 9531296
references.citation: Infect Immun. 2004 Apr;72(4):2412-5
references.pmid: 15039371
references.citation: Front Immunol. 2013 Jun 27;4:169
references.pmid: 23818888
references.citation: Mol Immunol. 2004 Feb;40(14-15):1009-17
references.pmid: 15036904
references.citation: Cell Immunol. 1996 Jan 10;167(1):44-55
references.pmid: 8548844
references.citation: Curr Opin Drug Discov Devel. 2007 May;10(3):332-40
references.pmid: 17554860